E. Rosen

发表

Tumour lineage shapes BRCA-mediated phenotypes

N. Socci, B. Taylor, N. Schultz, 2019, Nature.

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

B. Taylor, M. Ladanyi, A. Drilon, 2020, Clinical Cancer Research.

Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy.

A. Drilon, G. Iyer, Y. Murciano-Goroff, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors

A. Drilon, A. Schram, J. Hechtman, 2019, JCO precision oncology.

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

M. Galsky, K. Yonemori, C. Chappey, 2022, JAMA oncology.

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

M. Berger, A. Drilon, K. Offit, 2022, Nature Communications.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

M. Ladanyi, A. Drilon, A. Zehir, 2019, Modern Pathology.

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

B. Taylor, A. Drilon, A. Bardelli, 2019, Clinical Cancer Research.

A Performance Comparison of Commonly Used Assays to Detect RET Fusions

M. Ladanyi, A. Drilon, N. Rekhtman, 2020, Clinical Cancer Research.

Precision Oncology: 2022 in Review.

A. Drilon, D. Chakravarty, E. Rosen, 2022, Cancer discovery.

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

C. Bourque, B. Taylor, M. Ladanyi, 2022, Nature Communications.

Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance

M. Berger, S. Chandarlapaty, J. Reis-Filho, 2022, Cancer Research.

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

J. Reis-Filho, R. Plummer, F. Meric-Bernstam, 2023, Nature Medicine.

Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial

J. Reis-Filho, R. Plummer, S. Lheureux, 2022, Cancer Research.

Mechanisms of acquired resistance to TRK inhibitors.

A. Drilon, Y. Murciano-Goroff, A. Schram, 2022, Journal of Clinical Oncology.

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Jennifer L. Caswell-Jin, F. Meric-Bernstam, A. El-Khoueiry, 2022, Journal of Clinical Oncology.

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

M. Ladanyi, M. Berger, J. Reis-Filho, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.